Market research
300142.SHE Walvax Biotechnology Co., Ltd
SHE CNY Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 21B
- P/E ratio
- 108.33
- Analyst target
- 7
- Dividend yield
- 0.8%
- Beta
- 0.62
Community
Investor discussion
1 comment
Sign in to join the 300142.SHE discussion.
5 years, 5 months ago
Walvax Biotechnology Co., Ltd is currently in a long term uptrend where the price is trading 22.7% above its 200 day moving average.
From a valuation standpoint, the stock is 152.3% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 24.3.
Walvax Biotechnology Co., Ltd's total revenue rose by 323.9% to $1B since the same quarter in the previous year.
Its net income has increased by 2527.6% to $568M since the same quarter in the previous year.
Finally, its free cash flow fell by 15.2% to $-137M since the same quarter in the previous year.
Based on the above factors, Walvax Biotechnology Co., Ltd gets an overall score of 3/5.